With Doctor Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA
Associate Professor of Medicine,Division of Infectious Diseases,
Corporate Medical Director,Infection Prevention,Epidemiology,and Antibiotic Stewardship ,DMC and WSU Director,Infection Prevention,Epidemiology and Antibiotic Stewardship,Vibra Hospital
Dr. Chopra will lead the discussion with an overview of a C. difficile infection followed by Alba Muhlfeld, and Renata Johnson, C. diff. Survivors both sharing their journey and providing
key-points to our global listeners.
The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join Our Guest: Maureen Spencer, RN, M.Ed, CIC, will be joining us to continue discussing the coronavirus (COVID-19) through Prevention, Symptoms, and the global healthcare focus.
Patented alcohol-free quat technology with the versatility to use throughout healthcare settings with broad-spectrum disinfection
Clorox Healthcare is proud to announce the latest addition to its industry-leading portfolio of healthcare disinfectants: new Clorox Healthcare® VersaSureCleaner Disinfectant Wipes, an innovative, alcohol-free quat solution versatile enough to use on common healthcare surfaces with the assurance of broad-spectrum disinfection.
Clorox Healthcare® VersaSureCleaner Disinfectant Wipes are Environmental Protection Agency (EPA) registered to kill 44 pathogens, including bacteria, viruses and fungi, in two minutes or less. The unique, low odor, low residue formula features patented technology that enhances quat activity on surfaces to deliver broader efficacy and faster kill times without co-actives. The result is a versatile, one-step cleaner disinfectant wipe with the speed and efficacy healthcare facilities rely on and superior aesthetics, wetness and cleaning power needed for convenient, compliant use facility-wide.
Clorox Healthcare® VersaSureCleaner Disinfectant Wipes’ innovative new formula provides:
Speed and Strength Against Key Pathogens: VersaSure is EPA-registered to kill 44 microorganisms, including 14 multi-drug resistant pathogens, in two minutes or less. VersaSure kills influenza viruses, respiratory syncytial virus (RSV), measles, mumps and other viruses in 30 seconds1 and kills bacteria and fungi, including methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enterococcus faecalis (VRE), Escherichia coli (E. coli), salmonella, mycobacterium bovis (TB) and Candida albicans, in two minutes.
Excellent Aesthetics and Cleaning Power: Patented alcohol-free quat technology and innovative wipe design combine to provide excellent aesthetics, wetness and cleaning power. The low residue formula is designed for superior staff and patient comfort with no harsh chemical fumes or odors. Durable, low-linting wipes are textured for greater strength. Excellent wetness provides greater surface coverage compared with competitor quat and quat-alcohol disinfectant wipes and assurance that treated surfaces will remain wet for the full contact time.
Convenient, Compatible Use: VersaSure wipes are ready-to-use, fast acting and compatible with a broad range of hard, non-porous surfaces found in healthcare settings. A variety of sizes, including multipurpose wipes in 85 and 150 count canisters and 30 count flat packs, and terminal wipes for everyday cleaning and disinfecting of large spaces, available in 110 count buckets and refill pouches, makes VersaSure convenient for both nurses and environmental services teams to use facility-wide.
“Not all disinfectants are created equal and many don’t have the optimal balance of attributes to meet users’ needs. For example, a conventional quat or alcohol-based product might offer good compatibility, but have limited kill claims or evaporate from surfaces before meeting the required contact time,” says Brian Thompson, department manager – R&D, Clorox Healthcare. “We believe healthcare facilities shouldn’t have to make those trade-offs and with VersaSure, they don’t. Our R&D teams refused to make compromises between efficacy, aesthetics, wetness and cleaning power, and today we are excited to offer a one-step, ‘use everywhere’ wipe with broad-spectrum efficacy healthcare facilities can trust.”
Building the Industry’s Most Innovative, Comprehensive Portfolio of Disinfecting Solutions
In the fight against infections, today’s healthcare facilities need proven solutions to kill a broad range of pathogens, from seasonal threats like influenza and deadly pathogens like Clostridium difficile (C. difficile), to community-associated MRSA and new threats posed by emerging viral pathogens. Clorox Healthcare offers the industry’s most robust portfolio of EPA-registered surface disinfectants in addition to advanced UV technology, as well as cleaning and odor removal products to provide healthcare facilities, nurses and EVS professionals with a comprehensive portfolio of best-in-class solutions to help reduce the risk of infections and keep patients, staff, visitors and the broader community safe.
Clorox Healthcare understands that safeguarding healthcare environments requires advanced and evolving solutions. VersaSure joins products like Clorox Healthcare® Fuzion Cleaner Disinfectant, a new type of bleach that combines disinfecting efficacy against tough-to-kill pathogens like C. difficile spores with broad surface compatibility,
Clorox Healthcare® Bleach Germicidal Wipes and Clorox Healthcare® Hydrogen Peroxide Cleaner Disinfectants in a class of ready-to-use disinfectants that are tough on pathogens and optimized for surface compatibility, aesthetics, ease-of-use and patient and staff comfort to enable broad use, promote compliance and enhance safety facility-wide.
“At Clorox Healthcare, we are constantly innovating and working to expand the depth and breadth of our industry-leading portfolio, both by pushing the envelope with new product development and constantly striving for improvement to ensure that the mainstay surface disinfectants healthcare facilities depend on continue to meet the highest standards of efficacy and evolving needs of real-world healthcare environments,” says Lynda Lurie, director – marketing, Clorox Healthcare. “The expansion of our portfolio with the launch of VersaSure, brings us one step closer to our goal of removing the environment from the infection prevention equation.”
About Clorox Healthcare
Building on a century-long legacy in cleaning and disinfecting, Clorox Healthcare offers a wide range of products to help stop the spread of infection in healthcare facilities. From comprehensive surface disinfection to advanced ultraviolet technology, we are committed to providing efficacious solutions to the healthcare community. For more information, visit www.CloroxHealthcare.com or follow @CloroxHealth on Twitter.
The C Diff Foundation celebrates National Volunteer Week, April 23 – 29 to recognize more than 150 members of the C Diff Foundation Volunteer Members, including Volunteer Patient Advocates, have collectively donated more than 20,000 hours of volunteer service to the Foundation last year. The theme for this year’s celebration is “Sharing Time, Touching Lives.”
“Through the years the C Diff Foundation Volunteer Members have served as ambassadors of goodwill, service and compassion,” said Angelo Ortiz, C Diff Foundation’s Treasurer and Chairperson of the Volunteer Patient Advocate Program
The C Diff Foundation, a 501(c) (3) non-profit organization, established in 2012, and comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide
Not only do the volunteer members provide financial support for the C Diff Foundation’s programs — it is through their dedication and passion that continuously expands the Foundation’s mission. Some volunteer patient advocates have their own unique C. diff. Survivor Journey which is shared with compassion, dedication, and caring hearts touching patients, students, fellow healthcare professionals, and residents in the community every day.
Volunteer members will be recognized on November 9th & 10th during the C Diff Foundation’s 5th Annual International C. diff. Awareness Conference and Health EXPO being hosted
in Las Vegas, NV. During the annual event the “Volunteer Shooting Star” awards will
be presented along with numerous Volunteer Patient Advocate certificates for service hours.
“We are fortunate to have such kind and giving volunteers,” said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation, “It is an honor to recognize those who have selflessly given so much to help educate, and promote the Foundation’s mission worldwide.”
The C Diff Foundation Volunteer Program was organized in 2012 to provide volunteer services, promote community understanding of Clostridium difficile (C. diff.) CDI Infection Prevention, Treatments, Environmental Safety and Support and to raise funds for special C Diff Foundation patient/family programs.
The C Diff Foundation Members, with the Volunteer Patient Advocates, successfully promote
“C. diff. Awareness” nationwide and in fifty-six (56) countries and host a
U.S. Nationwide information Hot-Line (1-844-FOR-CDIF) to support health care providers, patients, and families guiding them through the difficulties caused by a C. diff. infection.
Volunteers Members serve in 12 different committees; Volunteers host monthly teleconference support sessions; Provide Education about C. diff. infection and other linked healthcare topics through workshops, community events, and literature with patients, their families, and residents from villages to cities around the globe; Triage Nurses assist patients, families, clinicians with answers to prevention, treatment, environmental safety and support questions Monday – Friday 9:00 a.m. – 5:00 p.m. EST; Register support session participants,; Provide IT management; Give clerical and social media assistance to various departments; Provide a “Global Broadcasting Network” with www.cdiffradio.com with their educational radio
program,C. diff. Spores and More which broadcasts live every Tuesday at 1:00 p.m. EST. We are grateful for our sponsor Clorox Healthcare for making this program possible. Each episode becomes a podcast and is accessible from the C. diff. Spores and More living library located on the main cdiffradio.com program page. Each Novemberthe Volunteer Members gather at the annual conference to both present and provide assistance in making the attendees feel welcome and expand their knowledge base on a variety of health topics that are linked to the main topic ~ Clostridium difficile infections.
For more information about the C Diff Foundation Volunteer Program, please call 919-201-1512 (toll free in USA 1-844-367-2343 ) or e-mail: firstname.lastname@example.org
C Diff Foundation Volunteers — Helping Us Help Others and The Beacon Of Light On the Other Side Of Pain and Suffering.
In the fight against healthcare-acquired infections (HAIs), today’s healthcare facilities need proven solutions to kill a broad range of infection-causing pathogens, from deadly hospital pathogens like Clostridium difficile (C. difficile) to new threats posed by emerging viral pathogens.
To ensure its disinfectants continue to meet the highest standards of efficacy, Clorox Healthcare voluntarily tested two of its leading ready-to-use bleach disinfectants using updated U.S. Environmental Protection Agency (EPA) recommended standards, which raise the bar for sporicidal disinfectant efficacy.
February 28th, 2017 Clorox Healthcare announced that Clorox Healthcare® Bleach Germicidal Wipes and Clorox Healthcare® Bleach Germicidal Cleaners are now EPA-registered to kill C. difficile spores in three minutes, tested in the presence of a three-part organic soil load, and have gained new disinfection claims for emerging viral pathogens including SARS-associated Coronavirus (SARS-CoV), Middle East Respiratory Syndrome-associated Coronavirus (MERS-CoV) and other common causes of HAIs.
“At Clorox Healthcare, we are dedicated to safeguarding patient environments and continuously strive to ensure our surface disinfectants meet the needs of the ever-changing healthcare environment,” says Lynda Lurie, Director – Marketing, Clorox Healthcare. “We made these changes proactively so that healthcare professionals can be prepared for whatever comes through their doors, wherever care is delivered.”
The new testing standards create a higher challenge for sporicidal disinfectant efficacy. Through voluntary testing, Clorox Healthcare Bleach Germicidal disinfectants have been able to maintain, and in some cases improve, contact times, killing 99.9999 percent of C. difficile spores – the EPA’s required threshold for efficacy – within three minutes, even in the presence of the three-part organic soil load.
*PLEASE NOTE – The C Diff Foundation does not endorse any products and/or clinical study in progress. All website postings are strictly for informational purposes only.